391 studies found for:    Open Studies | "Carcinoma, Hepatocellular"
Show Display Options
Rank Status Study
1 Recruiting Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Hepatoma;   Liver Cancer, Adult;   Liver Cell Carcinoma, Adult
Intervention: Drug: TKM-080301
2 Recruiting A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
Conditions: Liver Tumors;   Hepatocellular Carcinoma;   Hepatoma;   Neoplasms
Intervention: Device: TheraSphere®
3 Unknown  Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma
Conditions: Advanced Hepatocellular Carcinoma;   Metastatic Hepatocellular Carcinoma
Intervention: Drug: Sorafenib with Capecitabine and Oxaliplatin
4 Recruiting the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
Conditions: Stage I Hepatocellular Carcinoma;   Stage II Hepatocellular Carcinoma
Interventions: Drug: the ginsenoside Rg3;   Drug: Placebo
5 Recruiting Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients
Conditions: Cirrhosis With Hepatocellular Carcinoma;   Cirrhosis Without Hepatocellular Carcinoma
Interventions: Biological: Serum, plasma and DNA samples;   Procedure: Radiological exploration by CT scan or MRI
6 Recruiting Sorafenib and TRC105 in Hepatocellular Cancer
Conditions: Hepatoma;   Liver Neoplasms;   Adenoma, Liver Cell;   Carcinoma, Hepatocellular
Interventions: Drug: TRC 105;   Drug: Sorafenib
7 Recruiting A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
Conditions: Advanced Adult Hepatocellular Carcinoma;   Hepatocellular Carcinoma Metastatic
Intervention: Drug: AZD9150
8 Recruiting Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
Conditions: Hepatocellular Carcinoma;   Unresectable Hepatocellular Carcinoma;   Carcinoma, Hepatocellular;   Liver Neoplasm
Interventions: Drug: TACE with sorafenib;   Procedure: TACE alone
9 Recruiting Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: epirubicin;   Drug: Cisplatin
10 Recruiting Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Procedure: Transarterial Chemoembolization;   Radiation: Proton Beam Radiotherapy
11 Unknown  Proteomic Analysis of Human Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Procedure: Operation
12 Unknown  Effect of Polymorphisms in the IL-1 Gene Complex on the Development of Chronic Hepatitis and Hepatocellular Carcinoma
Conditions: Hepatitis B;   Carcinoma, Hepatocellular;   Polymorphism, Genetic
Intervention:
13 Recruiting Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Subjects With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: MSC2156119J;   Drug: Sorafenib
14 Recruiting Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria
Condition: Carcinoma, Hepatocellular
Interventions: Radiation: Proton Beam Radiotherapy;   Drug: Sorafenib
15 Unknown  Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
Conditions: Advanced Hepatocellular Carcinoma;   Carcinoma;   Carcinoma, Hepatocellular;   Liver Neoplasms;   Neoplasms
Interventions: Drug: Sorafenib with Low-dose FP;   Drug: Sorafenib
16 Not yet recruiting TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma
Conditions: PHENYTOIN/SORAFENIB [VA Drug Interaction];   Carcinoma, Hepatocellular
Interventions: Procedure: TACE;   Drug: sorafenib combined with TACE
17 Not yet recruiting Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
Conditions: PHENYTOIN/SORAFENIB [VA Drug Interaction];   Liver Neoplasms;   Carcinoma, Hepatocellular;   Digestive System Neoplasms;   Neoplasms by Site;   Liver Diseases;   Adenocarcinoma;   Carcinoma;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction];   HBV
Interventions: Procedure: Transarterial Chemoembolization (TACE);   Other: Sorafenib in combination with TACE
18 Recruiting c-Met Second-Line Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Drug: MSC2156119J
19 Recruiting Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
20 Recruiting Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma
Conditions: Carcinoma, Hepatocellular;   Alcoholic Cirrhosis;   Viral Cirrhosis;   Postoperative Hepatic Failure
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years